Co-inhibition of BET and proteasome enhances ER stres augmented cancer therapeutic efficacy

Cancer Letters

435, 44-54

DOI: 10.1016/j.canlet.2018.07.033

Citation Report

#	Article	IF	Citations
1	The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations. Translational Oncology, 2019, 12, 705-713.	1.7	20
2	The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. Cell Death and Disease, 2019, 10, 324.	2.7	11
3	ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptorâ€mutant nonâ€“small cell lung cancer cells to osimertinib. Cancer, 2020, 126, 1339-1350.	2.0	40
4	BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1. Cancer Research, 2020, 80, 2380-2393.	0.4	28
5	Overcoming acquired resistance of EGFRâ€mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. Molecular Oncology, 2020, 14, 882-895.	2.1	26
6	The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma. Cancers, 2021, 13, 1235.	1.7	16
7	Rictor, an essential component of mTOR complex 2, undergoes caspase-mediated cleavage during apoptosis induced by multiple stimuli. Apoptosis: an International Journal on Programmed Cell Death, 2021, 26, 338-347.	2.2	4
8	Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 7114.	1.8	2
9	Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. Cancer Research, 2021, 81, 4822-4834.	0.4	29
10	Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. Cancer Letters, 2021, 519, 141-149.	3.2	8
11	Overcoming acquired resistance of epidermal growth factor receptorâ€mutant nonâ€“small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer, 2020, 126, 2024-2033.	2.0	32
12	DOCK2 Promotes Pleural Fibrosis by Modulating Mesothelial to Mesenchymal Transition. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 171-182.	1.4	11
13	The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. American Journal of Cancer Research, 2020, 10, 3316-3327.	1.4	2
14	Dedicator of Cytokinesis 2 (DOCK2) Deficiency Attenuates Lung Injury Associated with Chronic High-Fat and High-Fructose Dietâ€“Induced Obesity. American Journal of Pathology, 2022, 192, 226-238.	1.9	12
15	Perfluorooctanoic acid induces hepatocellular endoplasmic reticulum stress and mitochondrial-mediated apoptosis in vitro via endoplasmic reticulum-mitochondria communication. Chemico-Biological Interactions, 2022, 354, 109844.	1.7	16
16	Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis. Neoplasia, 2022, 29, 100798.	2.3	5
17	Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1. Cancer Gene Therapy, 2022, 29, 1558-1569.	2.2	7
18	DOCK2 contributes to pulmonary fibrosis by promoting lung fibroblast to myofibroblast transition. American Journal of Physiology - Cell Physiology, 2022, 323, C133-C144.	2.1	8

#	Article	IF	Citations
19	Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway. Biochemical and Biophysical Research Communications, 2022, 623, 120-126.	1.0	2
20	Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	5
21	MLN2238 exerts its anti-tumor effects via regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma. Frontiers in Pharmacology, 0, 13, .	1.6	1